SEMA4D and Huntington disease: The SIGNAL phase 2 trial was designed to determine whether treatment with a SEMA4D-blocking antibody, pepinemab, is safe and well-tolerated in participants with EM or LP HD, and to assess efficacy in the EM cohort, as determined by cognitive, global (CGIC), functional and neuroimaging measures.